If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
You need a JavaScript-enabled browser to view this Publication
Please follow these steps to view the Publication:
Enable JavaScript in your browser
Refresh this page
Best regards
Zmags
European Edition
HEMATOLOGY
Suppl. 2 May 2020 emjreviews.com
+ ICML 2019
Antibody Therapies for
Patients With Diffuse Large
B-cell Lymphoma: What Does
the Future Hold?
Antibody Therapies for Patients With Diffuse Large
B-cell Lymphoma: What Does the Future Hold?
This symposium took place on 18th June 2019, as part of the 15th
International Congress on Malignant Lymphoma (ICML)
in Lugano, Switzerland
Chairpeople: Laurie H. Sehn1
Speakers: Armando López-Guillermo,2 Matthew Matasar,3 Franck Morschhauser,4
Laurie H. Sehn,1 Andrew McMillan5
1. British Columbia Cancer Centre for Lymphoid Cancer and University of British
Columbia, Vancouver, Canada
2. Department of Hematology, Hospital Clínic of Barcelona, Barcelona, Spain
3. Memoria
European Edition HEMATOLOGY Suppl. 2 May 202
Antibody Therapies for Patients With Diffuse Larg
chemotherapy. R-CHOP was later approved as first-l
The only positive trial published comparing
R-DHAP (dexamethasone, cytarabine, cisplatin) ver
antibody field; potential B-cell targets include a
There are many different BsAb constructs with dif
and degradation by lysosomes. The release of the
Proportion of event-free patients N=46; long-ter
Secondary outcome measures include event-free sur
2005;23(18):4117-26. 13. Thieblemont C et al. N
2019;20(1):31-42. 48. Schuster SJ. Tisagenlecleu
Oncology (ASCO) 2018, 1-5 June, 2018. 87. Sehn L